Document is current
Any future updates will be listed below
-
Authors
Runeberg-Roos, Pia https://orcid.org/0000-0001-9537-3982
Penn, Richard D
-
Funding
Funding for this research was provided by:
University of Helsinki including Helsinki University Central Hospital
- License Information
-
More Information
Article History
Received: 27 April 2020
Accepted: 6 July 2020
First Online: 28 July 2020
Compliance with ethical statements
:
: RP is the scientific advisor and stockholder in NTF therapeutics which holds the patent for the NRTN variant N4.
: This article is a review and thus, it does not cover any previously unpublished studies with human participants or animals performed by any of the authors.
